Oncolytics Biotech Inc T.ONC

USA Inflation Reduction Act (IRA) 2022 Re: Biotech and China

[Noteable]

December 2022 - "The White House and Congress are quietly reshaping the American economic relationship with the world’s second-largest economic power, enacting a strategy to limit China’s technological development that breaks with decades of federal policy and represents the most aggressive American action yet to curtail Beijing’s economic and military rise."

The new strategy, which the Biden administration internally calls its “protect agenda,” is being rolled out this fall and winter in a series of executive actions. In October, the Commerce Department issued new rules aimed at cutting off Chinese firms’ ability to manufacture advanced computer chips. They will soon be followed by an executive order creating new federal authority to regulate U.S. investments in China — the first time the federal government will exert such power over American industry – and an executive order to limit the ability of Chinese apps like TikTok to collect data from Americans. 

In particular, Sullivan has highlighted biotechnology and clean energy as two industries where the U.S. must not let China take the lead. But White House policymakers say those actions will be “carefully tailored” to affect only high-end, strategic products, and not cut off everyday commerce.  

“Clean tech, biotechnology — these are sectors that are poised for significant growth,” said a senior administration official, who spoke anonymously to detail administration policies. 

The new initiatives to curtail Chinese tech firms represent a shift from the optimistic stance toward technological development that defined American policy for decades. 

Throughout the end of the Obama administration and through Trump’s term, national security officials struggled to convince their colleagues in other agencies that commercial interests in the Chinese economy should, at least, be tempered by security considerations. 

In his September speech, Sullivan outlined three broad sectors where the administration would try to stall Chinese development: computing (including chips, quantum computing and artificial intelligence), biotechnology and biomanufacturing, and clean energy tech.

The U.S. government moves beyond the semiconductor sectors and seeks to stall or outpace China’s development in other critical sectors like biotech and clean energy

https://www.politico.com/news/2022/12/26/china-trade-tech-00072232

[Noteable]

Yesterday's "State of the Union" address was diplomatic on China but didn't change the USA's position in introducing IRA protective measures in high technology areas such as biotech and clean tech, for example. 

[Noteable]

The IRA works to protect investment in biologics while dissuading the same in small molecules, which are easiler to genericize and have a greater prominance in India.  Consequently Big Pharma companies will be pivoting to biologic products, and making large investments in biologic companies like ONCY with the I/O agent pelareorep, which has an extensive patent portfolio protecting the agent,

[Noteable]

" how did AN 'clear the way'?" .. This has already been fully answered. G'day.

[itntdf]

good luck with your "kellyanne conway" alternate facts.  let us know when you have completed your course work at the marjorie taylor buffoon school of lower education, mate.

[Noteable]

The IRA has set-out to protect US investment in biologics while dissuading the same in small molecules, which are easiler to genericize and have a greater prominance in India.  As a consequence, Roche is returning development and commercialization rights for cancer drug Gavreto to Blueprint Medicines. GAVRETO (pralsetinib) is a once-daily small molecule oral targeted therapy. 

[Noteable]

March 13, 2023 - "Unlike some of his pharma CEO peers who have lambasted the new law, Pfizer CEO Albert Bourla told investors on a call this morning that there are two specific factors pertaining to the IRA that will actually help with the combo of Pfizer and Seagen moving forward:   (1) The $2,000 out-of-pocket cap for seniors, which takes effect in 2025 and will mean that more of

[Noteable]

June 20, 2023 -  Astrazeneca is considering a corporate restructuring that could help it sidestep the tense confrontation between the US and China countries that has developed in the last few years, and with the United States passage of the IRA, by spinning its Chinese assets into a separately listed company in either Hong Kong or Shanghai. https://endpts.com/astrazeneca-ponders-a-china

[Noteable]

June 29, 2023 -  “Following the IRA passed last August, we continue to see a shift in the development of biologics over small molecules,” observes Ophelia Chan, a pharmaceutical business fundamental analyst at GlobalData. “In 2023, U.S.-based biotechs experienced a surge in venture financing for innovator biologic drugs, surpassing the funding for small molecules drugs by 48%.” 

[Noteable]

There are clear pathways that biopharma can take to sustain growth and remain competitive. Biopharma companies are seeking to use a mix of growth pathways to achieve their goals. Selecting the right pathway depends on the company's size, agility, and time horizon to achieve growth.  Four potential growth pathways include: Architect pathway. Early-stage asset acquisitions—often

[Noteable]

Future growth in the biopharma industry will increasingly focus on bio-platforms. Investing in a bio-platform, understanding the technology behind it, and mastering the repeatable operations enables efficiencies, speed, and lower costs, yielding a competitive advantage over firms following a traditional asset strategy.    ONCY's pelareorep is an immune molecule platform

[Noteable]

Should read: " ONCY's pelareorep is an immune molecule bio-platform technology that can be used to treat multiple cancers across multiple therapeutic areas (TAs). "

[Noteable]

Pelareorep is an immune molecule bio-platform technology that can be used to treat multiple cancers across multiple therapeutic areas = US$10 Billion to US$15 Billion M&A value.

[Noteable]

Looks as though that Roche/Genentech's Alexander Hardy doesn't have a good understanding on how the IRA is seeking to change the innovation landscape, since 13 years of FDA market exclusivity will be granted to novel biological drugs effective from the date of the FDA grants approval. With 13 years of market exclusivity being granted when the drug is approved doesn't squeeze companies

[Noteable]

I wonder if Novartis' decision to hand back BeiGene's Tigit candidate also has to do with the Inflation Reduction Act (IRA), which was passed earlier this year, and is meant to encourge US based biopharma companies to become competitive with China and to pull-away from doing business with Chinese based companies.

[Noteable]

Adlai Nortye reports in its July 27, 2023 SEC Form F-1 filing for an IPO in the United States that it may be restricted from transferring scientific data from China to foreign parties. Perhaps this is why Novartis handed China based BeiGene's TIGIT inhibitor back to BeiGene and why other Big Pharma companies are beginning to create 'spin-off' companies in China rather than continue a

[Noteable]

August 03, 2023 -  Another Big Pharma cuts ties with Chinese based pharma company BeiGene. BMS and BeiGene agreed to end a China licensing deal that BeiGene signed with Celgene back in 2017 before its acquisition by Bristol, an August 1st securities filing shows. In the original deal, Celgene essentially sold its China business, including local rights to cancer drugs Revlimid, Abraxane

[Noteable]

March 08, 2024 - Yesterday's "State of the Union Address" further emphasized that orphan/rare drugs would be exempt from future price negotiations while the White House is looking to increase the Inflation Reduction Act’s (IRA) current negotiation cap of 20 drugs per year to 50 drugs annually, focusing on medications crucial for seniors such as heart disease, cancer and diabetes

[Noteable]

Also from the "State of Union" address the Biden administration is also looking to expand the $2,000 cap on out-of-pocket spending for prescription drugs, which will apply to senior beneficiaries of Medicare by 2025. This move will add further incentive to the use of biologics like ONCY's pelareorep in combination with other oncology agents, like checkpoint inhibitors, small

[Noteable]

March 11, 2024 - Startups raised millions to in-license drugs to China. Then the model fell apart. https://endpts.com/startups-raised-millions-to-in-license-drugs-to-china-then-the-model-fell-apart/

[ENEMENEMYNEMO]

Oh got it now haha ...Notable is a bot... which I've been angry to... ha

[Lesalpes29]

Unstable is working hard for sure. Don't know if he is paid for? Just over 1.00 usd... his repetetive posts are not working well. GL anyway!

[Buckhenry]

Let's not forget about his mini me bot...assak 

[Noteable]

Bots don't make spelling mistakes ... so keep trying.

[13X2413]

Better Googleize that. Bots do make spelling mistakes.   

[Azzak34]

My my, you Fud folks jump up to 100's of views awful quick! Interesting.  I notice very few likes though so that should give you guys an indication of how your posts are received. Like a marzipan d1ldo. 

[Noteable]

Googleize ?? google-ize Urban Dictionary https://www.urbandictionary.com › define       when you are incompetent and need the answer to a burning question and consult

[Buckhenry]

They are Chinese bots... their AI chips are a bit flawed...

[ENEMENEMYNEMO]

This post has been removed in accordance with Community Policy

[Noteable]

March 13, 2024 - WuXi became a critical partner to biopharma companies. They’re not ready if the US cracks down.   It’s hard to disentangle WuXi AppTec’s rise from China’s. Over the last two decades, the Shanghai-based company grew from nothing into a research superstore for the world’s biopharma companies. https://endpts.com/wuxi-became-a-critical-partner-to-biopharma-companies-theyre

[Noteable]

March 14, 2024 - Trade group Biotechnology Industry Organization (BIO) announced Wednesday that it is cutting ties with WuXi AppTec as the lobby takes steps to “separate” from the China-based biotech from its membership. Wednesday’s decision comes after a congressional committee recently blasted the Biotechnology Industry Organization (BIO) for allegedly lobbying on behalf of

[Noteable]

In January 2024 the European Commission has granted marketing authorisation for Roche's Tecentriq® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection.  https://www.globenewswire.com/news-release/2024/01/16/2809494/0/en/European-Commission-approves-Roche-s-Tecentriq-SC-the-EU-s-first-PD-L-1-cancer-immunotherapy

[Noteable]

https://www.pharmaceutical-technology.com/data-insights/wuxi-apptec-patent-activity/?cf-view

[Noteable]

In the latest letter to US Commerce Secretary and Defense Secretary, lawmakers said the firms are together becoming an industry giant that threatens US intellectual property and national security. While WuXi AppTec said its business won’t pose security risks to any country, both stocks have suffered an intense selloff since last month. The Shanghai-based pharmaceuticals company said in a filing

[Noteable]

Adlai Norte's executive operates out of Hangzhou, China. https://www.adlainortye.com/index.php/about_team Yang (Carsten) Lu  Hangzhou,China CEO, Chairman of our Board of Directors   Wei (Vicky) Zhang, MS  Hangzhou/Hongkong,China Chief Financial Officer Donghui (Victor) Yang  Hangzhou,China

[Noteable]

March 29, 2024 - China-based biotech WuXi AppTec allegedly handed a U.S. client’s intellectual property over to the Chinese government without consent, according to an exclusive Reuters report on Thursday.  Citing sources who requested anonymity, Reuters reported that U.S. intelligence officials—led by the Federal Bureau of Investigation, the State

[Noteable]

An alleged development in the national security crackdown against WuXi AppTec and a handful of other Chinese companies in the U.S. suggests intelligence officials and lawmakers may have good reason to be concerned about the CDMO’s ties to its home country.  The latest update in the WuXi national security saga comes after a whirlwind of accusations against WuXi AppTec, its sister company WuXi

[Noteable]

April 02, 2024 - (Reuters) -A Republican and a Democratic member of Congress are calling on the Biden administration to add seven Chinese biotech firms to a list created by the Defense Department to highlight firms it says are allegedly working with Beijing's military.  U.S. intelligence officials in late February told senators working on the bill that Chinese pharmaceutical firm

[Noteable]

Chinese pharmaceutical group WuXi AppTec has said it is lobbying hard in Washington against a proposed bill that threatens its business in the US, where it generates 65 per cent of its revenues. WuXi AppTec is a major supplier of essential ingredients to many of the largest global pharmaceutical companies and conducts drug development for them.  Its sister company WuXi Biologics, conducts

[Noteable]

Some Big Pharma and Biotech CEO's appear not have gotten the message, which reinforces the solid understanding that these CEO's are well behind the curve. https://www.biospace.com/article/releases/cms-and-incyte-announce-collaboration-and-license-agreement-for-povorcitinib-in-china-and-southeast-asia/

[Noteable]

April 04, 2024 -  US-China tensions threaten to ensnare additional Chinese biopharma contractors In recent weeks, proposed federal legislation has forced US drugmakers to rethink their relationship with a Chinese company that’s a staple in drug development.Now, the industry is starting to wake up to the potential for restrictions on additional Chinese biotech contractors.   The

[Noteable]

April 04, 2024 - The Biosecure Act prohibits federal contracting with “certain biotechnology providers” tied to foreign adversaries. The biotech companies of concern listed in the proposed legislation are WuXi AppTec, BGI, MGI and Complete Genomics.  If signed into law, the legislation would prevent biopharma companies that contract with “companies of concern” from also having contracts with

[Noteable]

April 05, 2024 - Foreign investors fled Chinese biotech after the pandemic. They still haven’t come back Outside biotech money isn’t pouring into China like it used to.   In 2020 and 2021, venture investors put nearly $8 billion into Chinese biopharmas. But in the years that followed, those amounts have plunged as investors have sharply pulled back from China, according to

[itntdf]

Our license, development, supply, and distribution agreement with Adlai Nortye Biopharma Co. is subject to certain risks and uncertainties related to our dependence on Adlai and doing business in foreign jurisdictions.   On November 16, 2017, we announced that we had entered into a license, development, supply, and distribution agreement (the "Licensing Agreement") with Adlai

[Noteable]

November 16, 2017 was then ... and this is NOW !!

[Noteable]

https://foleyhoag.com/news-and-insights/publications/alerts-and-updates/2024/march/planning-for-the-biosecure-act/ Key Takeaways: Bipartisan legislation moving through the U.S. House and Senate, known as the BIOSECURE Act, could limit the ability of U.S. life sciences companies to contract with biotechnology companies with ties to the Chinese government or another “foreign adversary.”  

[Noteable]

April 26, 2024 – Washington- A House committee next month plans to mark up legislation that would restrict U.S. biotechnology companies from doing business with a Chinese company that makes key drug ingredients, according to five lobbyists tracking the BIOSECURE Act. The goal is for the House to pass the bill before the July 4 recess, setting it up to be included in a year-end must-pass

[Noteable]

April 23, 2024 - As the BIOSECURE Act threatens to upend relationships with Chinese contractors and western biopharma companies operating in the U.S., Novartis has elected not to adopt a “wait and see” attitude. Novartis, like many drugmakers, has ties to Chinese firms in the manufacturing and contract research space, the Swiss pharma’s CFO, Harry Kirsch, said on a press call Tuesday during its

[Noteable]

In June 2022  MorphoSys (the subject of Novartis February 2024 US$ 2.9 Billion acquisition) signed a new licensing and equity deal with I-Mab, a 100% Chinese owned and directed company. I-Mab was specifically granted rights to MOR210 in China, Hong Kong, Macau, Taiwan and South Korea, in accordance with a geographical carve-out in the deal with HIBio. On April 2, 2024, the Company

[Noteable]

https://www.i-mabbiopharma.com/leadership/#directors

[Noteable]

In 2017 MorophoSys announced that - I-Mab Biopharma (a fully owned affiliate of I-Mab) will assume exclusive responsibility for all subsequent development and commercialization of MOR202 in the agreed territory of  China, Taiwan, Hong Kong and Macao. https://finance.yahoo.com/news/ad-hoc-morphosys-increases-financial-110000262.html https://www.fiercebiotech.com/biotech/morphosys-sells

[Noteable]

The BIOSECURE Act, a proposed bipartisan legislation that aims to prohibit certain Chinese biopharmaceutical companies (and potentially other foreign entities from additional countries) from operating in U.S. markets due to perceived national security concerns, including claims that one of the companies named in the legislation has ties to the Chinese military. “This concept of Chinese civil

[Noteable]

April 25, 2024 - Bristol Myers Squibb (BMS) is working on contingency plans to “protect the continuity of supply” of medicine in preparation for draft US legislation seeking to restrict Chinese pharmaceutical companies over national security concerns, according to its finance chief. The Biosecure Act, introduced in the US Congress in January, would prohibit US companies receiving federal grant

[Noteable]

On Wednesday, 3 April, 2024, a letter from the House’s Select Committee on the Chinese Communist Party recommended more companies to add to the Pentagon’s list of firms that are allegedly working with the Chinese military. The letter identifies several companies, including two headquartered in California—Innomics (Sunnyvale, CA, US) and Axbio (Santa Clara, CA, US)—as potentially Chinese military

[Noteable]

May 01, 2024 - Amid a U.S. biosecurity crackdown targeting certain Chinese manufacturers and contract research organizations, production specialist WuXi Biologics has quietly exited what is perhaps the biotech industry’s biggest event of the year. WuXi Bio “will not have a presence” at the 2024 BIO International Convention in June, a spokesperson at the Biotechnology Innovation Organization has

[Noteable]

As for BIO, the trade group in March came out in support of the BIOSECURE Act, with the organization’s CEO, John Crowley, arguing that the U.S. and its allies should not allow “adversaries abroad” to further their goal to become the “biotechnology center of excellence in the world.” BIO made the public endorsement of the bill simultaneously with an announcement that WuXi AppTec had

[itntdf]

wuxi may have a backdoor to adlai: NEW JERSEY and HANGZHOU, CHINA, July 15, 2021 - (ACN Newswire) - Adlai Nortye Ltd. (hereinafter referred to as "Adlai Nortye"), a global biopharmaceutical company focused on developing innovative oncology drugs, today announced the completion of $100 million Series D financing round. Co-led by SDIC Fund Management and Tigermed, this

[Noteable]

WuXi and it's collaborative partners will be subject to the BIOSECURE ACT, notwithstanding Andrew de Guttadauro and his Chinese business interests.

[itntdf]

do you know if the biosecure act will be applied retrospectively or prospectively?

[Noteable]

Retrospectively or prospectively to what?

[Noteable]

Should trhe Biosecure Act be adopted - any US company doing business with any affiliate of the named Chinese companies will be precluded from benefiting trom any US federal programs, which is why Big Pharma is cutting ties with any Biotech company doing business with a plethora of Chinese companies both in Chine and the US.

[itntdf]

retrospective to prospective to when the law is passed. many companies already have contracts in place with wuxi or other problem entities on u.s. gov't. radar.  so, would this apply to contracts already in place or just future contracts after passage of the act?

[PeteZerria]

Sharing a NY Times piece from a few weeks ago regarding WuXi Apptech et al. I also own shares of IOVA, and WuXi is involved with Iovance at their iCTC manufacturing facility at the Philadelphia Navy Yard. Iovance mgmt not too concerned, at least publicly, since the CMO contract with WuXi was signed years ago. My takeaway is that even if WX goes away, Iovance can and will thrive. https://www

[Noteable]

Further to PeteZerria's post citing the NYT article - "A New York Times review of hundreds of pages of records worldwide shows that WuXi is heavily embedded in the U.S. medicine chest, making some or all of the main ingredients for multibillion-dollar therapies that are highly sought to treat cancers like some types of leukemia and lymphoma as well as obesity and H.I.V." "WuXi

[itntdf]

Judicial lawmaking traditionally operates both prospectively (like legislation) to affect future transactions and retrospectively (unlike most legislation) to affect past transactions.   Retroactive and retrospective laws raise questions of fairness and due process, as they can alter the legal consequences of past actions, while reactive laws focus on addressing and resolving existing

[Noteable]

If companies currently have contracts with WuXi, these same companies would do what Novartis is doing with MorphoSys, and/or they would exercise the force manjeure clause written into each contract.

[itntdf]

a force majeure provision may or may not apply.  a better contract protection would be a change in law provision.

[Noteable]

A "force majeure" clause (French for "superior force") is a contract provision that relieves the parties from performing their contractual obligations when certain circumstances beyond their control arise, making performance inadvisable, commercially impracticable, illegal, or impossible. - It applies in all incidences of contract law, particularly in incidences of

[itntdf]

de guttaduaro's wife, roshawn blunt, is on the board of kronos bio which also has a relationship with wuxi.   wuxi has meshed itself with a number of u.s. companies which is why the u.s. gov't is concerned about theft of intellectual property.

[Noteable]

March 7 Kronos Bio is cutting 21% of its workforce as part of a corporate restructuring that the company said would extend its cash runway into late 2026. Kronos—which currently has about 100 employees, according to Yahoo! Finance—announced in December that a key trial had failed in Phase Ib -  all under Roshawn Blunt's directorship. What does that say

[Noteable]

WuXi AppTec  embedded example:    David Y. H. Chang President and Chief Technology Officer at WuXi Advanced Therapies Dr. David Chang has more than 30 years of industrial experience. Before his current role, he was Chief Executive Officer WuXi AppTec Advanced Therapies Unit (ATU), prior to joining WuXi he was Corporate VP and Head of Cell Therapy Global Manufacturing, of

[Noteable]

https://phoenixmd.ca/management-team disappointing.since de Guttardauro got ONCY into a relationship through Bavencio - and the Bracelet-1 study - and should have known that Bavencio did not have an inactivated Fc component which resulted in the poor outcome of the Bavencio PD-L1 cohort of the Bracelet-1 study. de Guttardauro demonstrated his limited abiiities through this example and not being

[canadafan]

Maybe Andre2xdid not want to work for a us employeer. presumptuous ro determine why anyone would change jobs, or work anywhere at anytime. Always involves many factors. very few which are public.

[Noteable]

Why would de Guttadauro not work for a US company? He glorified his previous work with US companies, so if he didn't want to work for a US entity, why highlight that experience, unless he was seeking to embellish his psst, and that would be easily found out in the US.

[Noteable]

Why would de Guttadauro not work for a US company? - Perhaps also because de Guttadauro's general BD activities have been seemingly to leverage his Chinese business interests.

[Noteable]

On Wednesday, 3 April, 2024, a letter from the House’s Select Committee on the Chinese Communist Party recommended more companies to add to the Pentagon’s list of firms that are allegedly working with the Chinese military. The letter identifies several companies, including two headquartered in California—Innomics (Sunnyvale, CA, US) and Axbio (Santa Clara, CA, US)—as potentially Chinese military

[Noteable]

With respect to retroactive law -  any contracts with WuXi would not be able to be retroactively appllied in Tort Law pursuant to the passing of the Biosecure Act as per the Michigan Supreme Court. Lansing, Michigan decision in the case of ANDARY v USAA CASUALTY INSURANCE COMPANY (December 2023)  -  that opined the 2019 reforms, by their terms, apply to medical expenses and

[Noteable]

May 02, 2024 - According to co-sponsors of the bill, the BIOSECURE Act aims at addressing concerns stemming from “foreign adversaries’ hostile biotech pursuits”. The Act is also meant to stop the PRC government from acquiring American genomic data, as the Chinese military has allegedly invested in advancing their biotech and AI capabilities through joint business ventures with U.S. companies.

[itntdf]

that case is state law.  would guess if the biosecure act passes there will probably be federal cases brought one way or another and this will become a multi-jurisdictional case which could be consolidated because of nationwide implications given wuxi is currently operating in more than one state here in the u.s. will be interesting to see final language of the proposed bill and how that

[Noteable]

State Supreme Court rulings hold precedent and in Tort law usually appliies nationally unless appealed to and overrulled by the SCOTUS. The BIOSECURE ACT legislation has borrowed its language from Section 889, which is a law that blocks U.S. companies from entering into contracts with certain Chinese telecom giants and other companies. Endpoint News reported that entire phrases of Section 889 are

[itntdf]

the case you cited is michigan state law.  under no circumstances would a federal court second guess a state supreme court's interpretation of state law. state supreme court rulings on matters of state law are final. however, state supreme court rulings on matters of federal law can be appealed to scotus.  the ruling of one state's supreme court in not binding on another state

[Noteable]

Show me your evidence.

[itntdf]

i'm not your paralegal but here are a few places you can start to do your own dd: the "mcl's" and "pa's" cited in the case are michigan compiled laws and michigan public acts, not federal laws.

[Noteable]

I strongly advise you read up on Stare Decisis - a legal doctrine that obligates courts to follow historical cases when making a ruling on a similar or even a unique case, such that one State may refer to the precedent of other state that has an established ruling as a guide in setting its precedent. However, when the Supreme Court overturns a precedent made by courts below it in the legal

[itntdf]

your problem is that you cite federal laws in brown v boe and roe v wade.  you would be correct that in those cases states would have to follow supreme court decisions regarding federal law. the problem with your approach is that you cited the michigan case alleging it would bind other states or that it could be appealed to the supreme court.  just flatly not so.  state supreme

[Noteable]

intntdf - well it's very apparent that you don't know squwat about the law and have instead fallen back on "creative writing" to try to disguise your serious lack of knowledge .

[itntdf]

your apology is accepted while it's apparent you don't know "squwat" about "force manjuere". 

[Noteable]

Ok itntdf. Then tell me what you think I don't know, about force majeure, since you are so good at "creative writing" and "spreading sheet". Tell me about why it's written into most all contracts to protect the parties from unforseen happenings. Tell me why in contract law in the United States, most companies like to incorporate in Delaware. Tell me why in contract law

[13X2413]

I have no problem admitting you guys are way smarter than I'll ever be, but I'm sensing a bit of distress. I hope I'm misreading this. 

[Buckhenry]

It's nice to know unnoteable has two good skills... control C and V.  Or is that just one skill?  

[Noteable]

Stare decisis enhances the stability and predictability of tort law by ensuring that change is gradual. It recognizes that people rely on court rulings as existing law. The primary reason for changing precedent in all areas of law, particularly in constitutional law, is to overrule precedent that contains obvious or manifest error. This notwithstanding, tort law, and the procedural and

[Noteable]

Besides being accused of the collection of global genetic data and sharing it with the Chinese Communist Party in China, China's WuXi AppTec in Wuhan China, was at the epicenter of the Covid-19 outbreak, resulting in the shutting down of the global supply chain of APIs and negatively impacting the global health ecosystem and overall human health in a significant fashion. https://www

[Journeytc]

Noteable did they even know about the activated Fc when initiating that arm of the Bracelet?   Or did they learn from the trial?   Pfizer isnt a potted plant in this either.  I think some of the major pharma know more about pela that ONC doee.  Think the biomarker idea came from Roche? 

[Noteable]

I don't know when ONCY learned of the activated FC component of Bavencio. One would think it was in the literature available in the public domain and if de Guttadauro was doing his job he would have raised this matter in BD discussions, unless of course, this knowledge was well above what he knows, which further suggests the reason why he chose a pre-clinical Canadian company as his new

[Noteable]

April 10, 2024 - The Biosecure Act would prohibit US companies receiving federal grant money from working with four Chinese biotech companies, including WuXi AppTec and its sister company WuXi Biologics, which produce active pharmaceutical ingredients (API) for hundreds of US and European drugmakers.  Biotechnology has become one of Washington’s national security priorities, as the Biden

[Noteable]

The IRA is "a strategy to limit China’s technological development that breaks with decades of federal policy and represents the most aggressive American action yet to curtail Beijing’s economic and military rise." In particular, [Commerce Secretary] Sullivan has highlighted biotechnology and clean energy as two industries where the U.S. must not let China take

[Noteable]

May 10, 2023 - Eli Lilly’s Lilly chief scientific and medical officer Daniel Skovronsky is openly attacking a controversial clause in the new drug pricing law saying the law will discourage investments in small molecules. I think that Skovronsky needs to read my opinion piece on this matter in which I outlined how the IRA will provide biologics 13 years of FDA market exclsusivity

[Noteable]

As parallel news on Eli Lilly, Illinois federal judge Harry Leinenweber ruled today that Eli Lilly owes triple damages from last year's award after whistleblower Ronald Streck convinced a jury that the company violated the False Claims Act and short-changed Medicaid on rebate payments. The case dates to 2014, when whistleblower Streck—a pharmacist and lawyer—sued Eli Lilly

[Noteable]

April 11, 2024 - https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-inc?threadid=35999514